
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsIncyte Bolsters Hematology Growth With $2 Billion Vega BuyoutIncyte has agreed to acquire Vega Therapeutics for up to $2 billion, gaining VGA039, a first-in-class anti-Protein S monoclonal antibody in Phase 3 development for von Willebrand disease.…Fact-Checked
Mergers & AcquisitionsAlnylam Partners With Inceptive in Up to $2 Billion AI Drug Discovery DealAlnylam Pharmaceuticals has partnered with Inceptive Nucleics in a deal worth up to $2 billion to advance RNAi therapeutics through AI‑driven design.Fact-Checked
Mergers & AcquisitionsIDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic CancerIDEAYA Biosciences and Roche have partnered to evaluate the PRMT5 inhibitor IDE892 with the pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.Fact-Checked
Mergers & AcquisitionsAscidian Secures Up to $1.9 Billion in Lilly Kidney Disease PartnershipEli Lilly has entered a $1.9 billion collaboration with Ascidian Therapeutics to advance RNA exon editing therapies for monogenic kidney diseases.Fact-Checked
Mergers & AcquisitionsCytomX Secures Expanded Regeneron Partnership Worth Up to $4 BillionCytomX Therapeutics and Regeneron Pharmaceuticals have broadened their 2022 oncology collaboration, adding new targets and strengthening efforts to advance conditionally activated bispecific immunotherapies designed to improve safety and…Fact-Checked
Mergers & AcquisitionsCEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 MillionModerna has expanded its collaboration with CEPI to accelerate development of an investigational mRNA vaccine against Bundibugyo ebolavirus.Fact-Checked
Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 BillionServier has agreed to acquire Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, securing late-stage investigational therapy sevasemten for Becker and Duchenne muscular dystrophies.Fact-Checked
Mergers & AcquisitionsAgios Lands Global Cevidoplenib Rights in Rare Hematology PushAgios Pharmaceuticals has secured worldwide rights to cevidoplenib, a next‑generation SYK inhibitor from Oscotec, in a $25 million licensing deal with milestone and royalty potential.Fact-Checked
Mergers & AcquisitionsPfizer and Innovent Strike Oncology Deal Worth Up to $10.5 BillionPfizer and Innovent Biologics have formed a global oncology partnership worth up to $10.5 billion to advance 12 early-stage cancer programs spanning antibody-drug conjugates and multispecific antibodies.Fact-Checked
Mergers & AcquisitionsApogee Secures Up to $1.3 Billion From Blackstone to Advance Zumilokibart in Atopic DermatitisApogee Therapeutics has entered a strategic financing agreement with Blackstone Life Sciences valued at up to $1.3 billion, combining synthetic royalty funding and optional senior debt to support…Fact-Checked
Mergers & AcquisitionsLilly Acquires Curevo, LimmaTech, and Vaccine Company to Expand Vaccine PortfolioEli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.Fact-Checked
Mergers & AcquisitionsGilead Renews WHO Partnership to Fight Visceral LeishmaniasisGilead Sciences and the World Health Organization have expanded their collaboration to combat visceral leishmaniasis (VL), one of the world’s deadliest neglected tropical diseases.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.